补充鱼油对 2 型糖尿病患者血糖控制和血脂水平的影响：随机对照试验的荟萃分析。,Lipids in Health and Disease

当前位置： X-MOL 学术 › Lipids Health Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

补充鱼油对 2 型糖尿病患者血糖控制和血脂水平的影响：随机对照试验的荟萃分析。
Lipids in Health and Disease ( IF 3.9 ) Pub Date : 2020-05-08 , DOI: 10.1186/s12944-020-01214-w
Chao Gao ₁ , Yang Liu ₁ , Yong Gan ₂ , Wei Bao ₃ , Xiaolin Peng ₄ , Qingbin Xing ₁ , Huiyu Gao ₁ , Jianqiang Lai ₁ , Liegang Liu ₂ , Zhu Wang ₁ , Yuexin Yang ₁

Affiliation

背景先前的研究对于鱼油在 2 型糖尿病 (T2DM) 中的作用得出了不一致的结果。我们系统地总结了随机对照试验 (RCT) 的现有证据，旨在研究补充鱼油对 T2DM 患者血糖控制和血脂水平的影响。方法全面检索电子数据库（PubMed、ProQuest、Cochrane Library、CNKI、VIP、万方）中截至2019年5月31日发表的所有相关RCT，采用Modified Jadad Score系统评价质量每个纳入的随机对照试验。使用随机效应模型估计汇总效应，并以 95% 置信区间的标准化平均差表示。结果本荟萃分析共纳入 12 项随机对照试验。与安慰剂相比，补充鱼油的血糖控制结果没有显着差异。空腹血糖 (FPG) 的效应大小为 0.13 (95% CI: - 0.03 至 0.28, p > 0.05)。空腹胰岛素 (FINS)、糖化血红蛋白 (HbA1c) 和胰岛素抵抗 HOMA (HOMA-IR) 水平没有观察到明显变化。补充鱼油与甘油三酯 (TG) 水平降低 - 0.40 (95%CI: - 0.53 至 - 0.28, p < 0.05) 相关，并使高密度脂蛋白 (HDL) 胆固醇水平增加 0.21 (95% CI) CI：0.05 至 0.37，p < 0.05）。在亚组分析中，亚洲亚组和低剂量 (< 2 g/d n-3 PUFA) 亚组的 HDL 胆固醇水平高于相应亚组 (p < 0.05)。中、长病程组TG水平较低，短病程组差异不明显。结论这项荟萃分析表明，在 T2DM 患者中，补充鱼油可以改善血脂状况，但不能改善血糖控制。

"点击查看英文标题和摘要"

Effects of fish oil supplementation on glucose control and lipid levels among patients with type 2 diabetes mellitus: a Meta-analysis of randomized controlled trials.

BACKGROUND Previous studies have yielded inconsistent findings on the role of fish oil in type 2 diabetes mellitus (T2DM). We systematically summarized the available evidence from randomized controlled trials (RCT) and aimed to investigate the effects of fish oil supplementation on glucose control and lipid levels among patients with T2DM. METHODS A comprehensive literature search was performed in electronic databases (PubMed, ProQuest, Cochrane Library, CNKI, VIP, and Wanfang) to identify all relevant RCTs which were published up to May 31st, 2019. We used Modified Jadad Score system to evaluate the quality of each included RCT. The pooled effects were estimated using random-effects model and presented as standardized mean differences with 95% confidence intervals. RESULTS A total of 12 RCTs were included in this meta-analysis. There was no significant difference in glucose control outcomes comparing fish oil supplementation to placebo. The effect size of fasting plasma glucose (FPG) was 0.13 (95% CI: - 0.03 to 0.28, p > 0.05). No marked change was observed in fasting insulin (FINS), glycosylated hemoglobin (HbA1c), and HOMA of insulin resistance (HOMA-IR) levels. Fish oil supplementation was associated with a decrease of triglyceride (TG) level by - 0.40 (95%CI: - 0.53 to - 0.28, p < 0.05), and an increase of high density lipoprotein (HDL) cholesterol level by 0.21 (95%CI: 0.05 to 0.37, p < 0.05). In subgroup analysis, HDL cholesterol level was higher among Asian and low-dose(< 2 g/d n-3 PUFA) subgroups compared to their counterparts (p < 0.05). TG level was lower in mid and long duration groups, along with an inconspicuous difference in short duration group. CONCLUSIONS This meta-analysis shows that among patients with T2DM, fish oil supplementation leads to a favorable blood lipids profile but does not improve glucose control.

更新日期：2020-05-08

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>